PRTA - Prothena Corporation plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Prothena Corporation plc

77 Sir John Rogerson's Quay
Block C Grand Canal Docklands
Dublin 2
Ireland
353 1 236 2500
http://www.prothena.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees59

Key Executives

NameTitlePayExercisedYear Born
Mr. Gene G. KinneyPres, CEO & Director820.88kN/A1969
Mr. Tran B. NguyenCFO & COO598.02kN/A1974
Dr. Wagner M. ZagoChief Scientific Officer478.79kN/A1973
Ms. Carol D. KarpChief Regulatory Officer574.99kN/A1953
Ms. Karin L. WalkerChief Accounting Officer & ControllerN/AN/A1963
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Celgene Corporation to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.

Corporate Governance

Prothena Corporation plc’s ISS Governance QualityScore as of June 25, 2019 is 8. The pillar scores are Audit: 1; Board: 4; Shareholder Rights: 5; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.